 Kazia Therapeutics Ltd ASX:KZA NASDAQ:KZIA FRA:NV9 has entered into a licensing agreement with Simcere Pharmaceutical Group Ltd HKSE:2096 to develop and commercialise Kazias investigational new drug, paxalisib, in Greater China. Simcere will assume responsibility for the development, registration and commercialisation of paxalisib in Greater China - which includes mainland China, Hong Kong, Macau, and Taiwan. 